Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K, Krais JJ, Wang Y, Vandenberg CJ, Patel P, Cai KQ, Kwan T, Lieschke E, Ho GY, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Kyran E, Betsch R, Xu L, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, McNeish I, Ratnayake G, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Bowtell DDL, Harding TC, Lin K, Swisher EM, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. Nesic K, et al. Among authors: ho gy. Mol Cancer. 2024 Aug 5;23(1):158. doi: 10.1186/s12943-024-02048-1. Mol Cancer. 2024. PMID: 39103848 Free PMC article.
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer.
Xu H, Gitto SB, Ho GY, Medvedev S, Shield-Artin K, Kim H, Beard S, Kinose Y, Wang X, Barker HE, Ratnayake G, Hwang WT; Australian Ovarian Cancer Study; Hansen RJ, Strouse B, Milutinovic S, Hassig C, Wakefield MJ, Vandenberg CJ, Scott CL, Simpkins F. Xu H, et al. Among authors: ho gy. iScience. 2024 May 15;27(7):109978. doi: 10.1016/j.isci.2024.109978. eCollection 2024 Jul 19. iScience. 2024. PMID: 39021796 Free PMC article.
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Ho GY, Vandenberg CJ, Lim R, Christie EL, Garsed DW, Lieschke E, Nesic K, Kondrashova O, Ratnayake G, Radke M, Penington JS, Carmagnac A, Heong V, Kyran EL, Zhang F, Traficante N; Australian Ovarian Cancer Study; Huang R, Dobrovic A, Swisher EM, McNally O, Kee D, Wakefield MJ, Papenfuss AT, Bowtell DDL, Barker HE, Scott CL. Ho GY, et al. Ther Adv Med Oncol. 2023 Nov 22;15:17588359231208674. doi: 10.1177/17588359231208674. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38028140 Free PMC article.
Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Marks ZRC, Campbell NK, Mangan NE, Vandenberg CJ, Gearing LJ, Matthews AY, Gould JA, Tate MD, Wray-McCann G, Ying L, Rosli S, Brockwell N, Parker BS, Lim SS, Bilandzic M, Christie EL, Stephens AN, de Geus E, Wakefield MJ, Ho GY, McNally O; Australian Ovarian Cancer Study; McNeish IA, Bowtell DDL, de Weerd NA, Scott CL, Bourke NM, Hertzog PJ. Marks ZRC, et al. Among authors: ho gy. Nature. 2023 Aug;620(7976):1063-1070. doi: 10.1038/s41586-023-06421-w. Epub 2023 Aug 16. Nature. 2023. PMID: 37587335
NETosis as an oncologic therapeutic target: a mini review.
Jaboury S, Wang K, O'Sullivan KM, Ooi JD, Ho GY. Jaboury S, et al. Among authors: ho gy. Front Immunol. 2023 Apr 18;14:1170603. doi: 10.3389/fimmu.2023.1170603. eCollection 2023. Front Immunol. 2023. PMID: 37143649 Free PMC article. Review.
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K, Krais JJ, Vandenberg CJ, Wang Y, Patel P, Cai KQ, Kwan T, Lieschke E, Ho GY, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Kyran E, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, Ratnayake G, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Bowtell DDL, Harding TC, Lin K, Swisher EM, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. Nesic K, et al. Among authors: ho gy. medRxiv [Preprint]. 2023 Aug 28:2023.03.20.23287465. doi: 10.1101/2023.03.20.23287465. medRxiv. 2023. Update in: Mol Cancer. 2024 Aug 5;23(1):158. doi: 10.1186/s12943-024-02048-1 PMID: 36993400 Free PMC article. Updated. Preprint.
151 results